Athersys Announces Favorable Preclinical Results for MultiStem® Treatment in Defense Department Radi

CLEVELAND--(BUSINESS WIRE)--$ATHX #ARS--Athersys, Inc. (Nasdaq: ATHX) announces today results of a radiation countermeasure study conducted by the Armed Forces Radiobiology Research Institute (AFRRI), a Department of Defense research laboratory under the leadership of the Uniformed Services University of the Health...

Related Keywords

Hiroshima ,Japan ,Ellen Gurley ,Dan Camardo ,Sarah Busch ,Robertw Mays ,Linkedin ,Twitter ,Department Of Defense ,National Institute Of Allergy ,Nasdaq ,Armed Forces Radiobiology Research Institute ,Athx Inc ,Corporate Communications ,Regenerative Medicine Head Of Nonclinical Development ,Facebook ,Uniformed Services University Of The Health Sciences ,Uniformed Services University ,Health Sciences ,Chief Executive Officer ,National Institute ,Infectious Diseases ,Immune System ,Cellular Platform ,Treating Disease ,Multipotent Adult Progenitor Cells ,Vice President ,Regenerative Medicine ,Nonclinical Development ,Eastern Time ,Radiation Syndrome ,Private Securities Litigation Reform Act ,Annual Report ,